1 / 6

Impact of ACE inhibitors and Angiotensin II receptor blockers on all- cause mortality in hypertension trials

Congress of the European Society of Cardiology Oral presentation. Sunday August 28, 2011. Impact of ACE inhibitors and Angiotensin II receptor blockers on all- cause mortality in hypertension trials. Collaborative group: Michel E. BERTRAND, MD, FRCP (London), FESC, FACC, FAHA

adriana
Download Presentation

Impact of ACE inhibitors and Angiotensin II receptor blockers on all- cause mortality in hypertension trials

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Congress of the European Society of Cardiology Oral presentation. Sunday August 28, 2011 Impact of ACE inhibitors and Angiotensin II receptor blockers on all- cause mortality in hypertension trials Collaborative group: Michel E. BERTRAND, MD, FRCP (London), FESC, FACC, FAHA Lille University Heart Hospital, Lille, France Jean-Jacques MOURAD, MD, PhD Avicenne Hospital, Bobigny, France Kim FOX, Professor of Clinical Cardiology Department of Cardiology, Royal Brompton Hospital, London, UK Eric BOERSMA, MSc, PhD, FESC Erasmus MC, Department of Cardiology, Rotterdam, The Netherlands Laura VAN VARK, MD, MSc Erasmus MC, Department of Cardiology, Rotterdam, The Netherlands M. Bertrand. Oral session ESC, Paris 2011

  2. A pooled analysis of morbidity-mortality trials Inclusion criteria: Morbidity-mortality trials including ACE or ARBs inhibitors in treatment arms conducted from 2000 to June 2010 Trials including mainly hypertensive patients ( >66% of studied population, according to the trial-specific definition) All-cause mortality: a pre-specified or reported in the principal study publication (an integrative end point taking into account both the benefits and severe adverse events of treatment devoided of bias or uncertainty) Exclusion criteria: Heart failure/acute coronary syndromes/acute stroke/ hemodialysis/atrial fibrillation or post-cardiac surgery trials Objective:To evaluate the impact of RAAS inhibitors on further mortality reduction in their main indication, hypertension, in patients representative of those treated in the XXIst century. M. Bertrand. Oral session ESC, Paris 2011

  3. Study population: 165 971 patients M. Bertrand. Oral session ESC, Paris 2011

  4. All-cause mortality: treatment effect of ACE inhibitors 7 ACE inhibitor trials: 88,860 patients Lisinopril 0.99 (0.92-1.06) Trandolapril 0.98 (0.89-1.08) Enalapril/imidapril/ lisinopril 0.94 (0.78-1.14) Perindopril 0.87 (0.81-0.94)* *P<0.001 Overall 0.94 (0.90-0.98)** ** P=0.007 0,8 0.9 1.0 1.1 1.2 ACE inhibitor better Control better M. Bertrand. Oral session ESC, Paris 2011

  5. All-cause mortality: treatment effect of ARBs 12 ARBs trials: 77111 patients Relative weight Losartan 0.92 (0.82-1.03) 16.9% Irbesartan 1.04 (0.77-1.40) 2.6% Candesartan 1.00 (0.86-1.17) 9.8% Valsartan 0.99 (0.91-1.07) 35.9% Eprosartan 1.08 (0.74-1.57) 1.6% Telmisartan 1.03 (0.95-1.12) 33.2% Overall 0.99 (0.95-1.04)* 100% *P=0.75 ARB better Control better P for heterogeneity 0.75; I² 0% M. Bertrand. Oral session ESC, Paris 2011

  6. Conclusion • Among RAAS inhibitors, only ACE inhibitors have demonstrated a further significant 6% mortality reduction in hypertensive patients (P=0.007) • No significant reduction in all-cause mortality could be demonstrated with ARBs (HR, 0.99 (0.95-1.04), P=0.75) • Perindopril significantly reduced all-cause mortality by 13% among contemporary patients with arterial hypertension (P<0.001) • Treatment with ACE inhibitors would additionally save 12 lives for every 1 000 patients treated for 4 years M. Bertrand. Oral session ESC, Paris 2011

More Related